The Era of Direct-Acting Antivirals Has Begun: The Beginning of the End for HCV?

ABSTRACT

The year 2011 marks the dawn of the new era of direct-acting antivirals for hepatitis C. For the first time since 1998, the U.S. Food and Drug Administration approved two new antiviral drugs for the treatment of chronic hepatitis C virus genotype 1. Dual therapy with pegylated interferon and ribavirin is no longer the standard of care for genotype 1. The new treatment paradigm includes one direct-acting antiviral, a protease inhibitor, in combination with pegylated interferon and ribavirin. This combination nearly doubles the chances of response to treatment, but at the cost of increased toxicity. Many agents with different mechanisms of action and improved safety profiles are in clinical development. The holy grail of HCV treatment is an all oral, interferon-free treatment. The ideal regimen will be potent, well tolerated, with minimal drug–drug interactions and once daily. This article covers new concepts of treatment of hepatitis C with DAAs and gives an overview of the recent highlights in direct-acting antiviral development.

KEYWORDS

Hepatitis C - treatment - direct-acting antivirals

REFERENCES

• 1 Kieffer T L, Kwong A D, Picchio G R. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs).  J Antimicrob Chemother. 2010;  65 (2) 202-212
• 2 Moradpour D, Penin F, Rice C M. Replication of hepatitis C virus.  Nat Rev Microbiol. 2007;  5 (6) 453-463
• 3 Pawlotsky J M, Chevaliez S, McHutchison J G. The hepatitis C virus life cycle as a target for new antiviral therapies.  Gastroenterology. 2007;  132 (5) 1979-1998
• 4 Ogata N, Alter H J, Miller R H, Purcell R H. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus.  Proc Natl Acad Sci U S A. 1991;  88 (8) 3392-3396
• 5 Bartels D J, Zhou Y, Zhang E Z et al.. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.  J Infect Dis. 2008;  198 (6) 800-807
• 6 Pawlotsky J M. Hepatitis C virus genetic variability: pathogenic and clinical implications.  Clin Liver Dis. 2003;  7 (1) 45-66
• 7 Susser S, Welsch C, Wang Y et al.. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.  Hepatology. 2009;  50 (6) 1709-1718
• 8 Sarrazin C, Kieffer T L, Bartels D et al.. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.  Gastroenterology. 2007;  132 (5) 1767-1777
• 9 Wagner F, Thompson R, Kantaridis C et al.. Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients.  Hepatology. 2011;  54 (1) 50-59
• 10 McCown M F, Rajyaguru S, Kular S, Cammack N, Nájera I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.  Antimicrob Agents Chemother. 2009;  53 (5) 2129-2132
• 11 Lee S S, Ferenci P. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4.  Antivir Ther. 2008;  13 (Suppl 1) 9-16
• 12 Jacobson I M, McHutchison J G, Dusheiko G ADVANCE Study Team et al. Telaprevir for previously untreated chronic hepatitis C virus infection.  N Engl J Med. 2011;  364 (25) 2405-2416
• 13 Poordad F, McCone Jr J, Bacon B R SPRINT-2 Investigators et al. Boceprevir for untreated chronic HCV genotype 1 infection.  N Engl J Med. 2011;  364 (13) 1195-1206
• 14 Sulkowski M S, Ceasu E, Asselah T et al.. SILEN-C1: sustained virologic response (SVR) and safety of BI 201335 combined with peginterferon alfa-2a and ribavirin (P/R) in treatment-naive patients with chronic genotype 1 HCV.  J Hepatol. 2011;  54 (Suppl 1) S27
• 15 Zeuzem S, Andreone P, Pol S REALIZE Study Team et al. Telaprevir for retreatment of HCV infection.  N Engl J Med. 2011;  364 (25) 2417-2428
• 16 Lin T I, Lenz O, Fanning G et al.. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.  Antimicrob Agents Chemother. 2009;  53 (4) 1377-1385
• 17 Fried M W, Buti M, Dore G J et al.. Efficacy and safety of TMC435 in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 1 HCV patients: 24 week interim results from the PILLAR study.  Hepatology. 2010;  52 (Suppl 1) 107A
• 18 Huisman M T, Snoeys J, Monbaliu J et al.. In vitro studies investigating the mechanisms of interaction between TMC435 and hepatic transporters.  Hepatology. 2010;  52 (Suppl 1) 461A
• 19 Sulkowski M S, Bourliere M, Bronowicki J P et al.. SILEN-C2: sustained virologic response (SVR) and safety of BI201335 combined with peginterferon alfa-2a and ribavirin (P/R) in chronic HCV genotype-1 patients with non-response to P/R.  J Hepatol. 2011;  24 (Suppl 1) S30
• 20 Sane R, Podila L, Mathur A et al.. Mechanisms of isolated unconjugated hyperbilirubinemia induced by the HCV NS3/4A protease inhibitor BI201335.  J Hepatol. 2011;  54 (Suppl 1) S488
• 21 Detishin V, Haazen R, Hooijmaijers R et al.. Final results of the pharmacokinetics, efficacy, safety/tolerability of 400 and 600 mg once-daily dosing of ACH-1625 (HCV NS3 protease inhibitor) in HCV genotype 1.  J Hepatol. 2011;  54 (Suppl 1) S186-S187
• 22 Forestier N, Larrey D, Marcellin P et al.. Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.  J Infect Dis. 2011;  204 (4) 601-608
• 23 Gane E J, Rouzier R, Stedman C et al.. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients.  J Hepatol. 2011;  55 (5) 972-979
• 24 Terrault N, Cooper C, Balart L A et al.. Phase II randomized, partially blind, parallel-group study of oral danoprevir (RG7227) with PegIFN alfa-2a (PEGASYS) plus ribavirin (COPEGUS) in treatment-naive genotype 1 patients with CHC: results of planned week 12 interim analysis of the ATLAS study.  Hepatology. 2010;  52 (Suppl 1) 73A
• 25 Rouzier R, Larrey D, Gane E J et al.. Danoprevir plus low-dose ritonavir (DNV/R) in combination with peginterferon alfa-2a (40KD) plus ribavirin (PEGIFN-2a/RBV) in previous null responders.  J Hepatol. 2011;  54 (Suppl 1) S28
• 26 Lok A S, Gardiner D, Lawitz E et al.. Quadruple therapy with BMS-790052, BMS-650032 and Peg-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders.  J Hepatol. 2011;  54 (Suppl 1) S536
• 27 Mcphee F, Hernandez D, Yu F et al.. Charcterization of virologic escape in HCV genotype 1 null responders receiving a combination of the NS3 protease inhibitor BMS-650032 and NS5A inhibitor BMS-790052.  J Hepatol. 2011;  54 (Suppl 1) S28-S29
• 28 Foster G R, Buggisch P, Marcellin P et al.. Four-week treatment with GS-9256 and tegobuvir (GS-9190) ± RBV ± PEG, results in enhanced viral suppression of follow-up PEG/RBV therapy, in genotype 1a/1b HCV patients.  J Hepatol. 2011;  54 (Suppl 1) S172
• 29 Wong K A, Bae A, Ku K et al.. Genotypic and phenotypic characterization of HCV resistance from a multiple dose clinical trial of GS-9451, a novel NS3 protease inhibitor.  J Hepatol. 2011;  54 (Suppl 1) S493
• 30 Tong L, Mwangi J, Roy A et al.. In vitro studies on the potential for the hepatitis C virus protease inhibitors GS-9256 and GS-9451 to affect bilirubin elimination.  J Hepatol. 2011;  54 (Suppl 1) S487
• 31 Lawitz E, Rodriguez-Torres M, Denning J et al.. Once daily dual-nucleotide combination of PSI-938 and PSI-7977 provides 94% HCV RNA <LOD at day 14: first purine/pyrimidine clinical combination cata (The NUCLEAR Study).  J Hepatol. 2011;  54 (Suppl 1) S543
• 32 Lalezari J, Lawitz E, Rodriguez-Torres M et al.. Once daily PSI-7977 plus PEGIFN/RBV in a phase 2b trial: rapid virologic suppression in treatment-naïve patients with GT2/GT3.  J Hepatol. 2011;  54 (Suppl 1) S28
• 33 McCown M F, Rajyaguru S, Le Pogam S et al.. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors.  Antimicrob Agents Chemother. 2008;  52 (5) 1604-1612
• 34 Lawitz E, Rodriquez-Torres M, Rustgi V K et al.. Safety and antiviral activity of ANA598 in combination with pegylated interferon α2A plus ribavirin in treatment-naïve genotype 1 chronic HCV patients.  J Hepatol. 2010;  52 (Suppl 1) S467
• 35 Gao M, Nettles R E, Belema M et al.. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.  Nature. 2010;  465 (7294) 96-100
• 36 Tellinghuisen T L, Foss K L, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein.  PLoS Pathog. 2008;  4 (3) e1000032
• 37 Qiu D, Lemm J A, O’Boyle II D R et al.. The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization.  J Gen Virol. 2011;  92 (Pt 11) 2502-2511
• 38 Nettles R E, Gao M, Bifano M et al.. Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.  Hepatology. 2011;  Epub ahead of print
• 39 Fridell R A, Wang C, Sun J H et al.. Genotypic and phenotypic analysis of variants resistant to HCV NS5A replication complex inhibitor BMS-790052: in vitro and in vivo correlations.  Hepatology. 2011;  Epub ahead of print
• 40 Fridell R A, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.  Antimicrob Agents Chemother. 2010;  54 (9) 3641-3650
• 41 Crabbé R, Vuagniaux G, Dumont J M, Nicolas-Métral V, Marfurt J, Novaroli L. An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C.  Expert Opin Investig Drugs. 2009;  18 (2) 211-220
• 42 Flisiak R, Feinman S V, Jablkowski M et al.. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.  Hepatology. 2009;  49 (5) 1460-1468
• 43 Flisiak R, Pawlotsky J, Crabbé R et al.. Once daily alisporivir (Deb025) plus PEGIFNalfa2a/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment naïve patients.  J Hepatol. 2011;  54 (Suppl 1) S2
• 44 Coelmont L, Hanoulle X, Chatterji U et al.. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A.  PLoS ONE. 2010;  5 (10) e13687